It is interesting that the combinatorial targeting of MTCH1 and Sorafenib treatment showed a significant inhibitory effect on the growth of cervical cancer (97.8%) that was more efficient than MTCH1-deficiency (27.3%) or Sorafenib (75.6%) alone (Fig. 6D–F; P < 0.001, combined treatment versus MTCH1-deficiency; P < 0.001, combined treatment versus Sorafenib), suggesting that the MTCH1-deficiency and Sorafenib acted, at least in part, on different pathways. Here, MTCH1 is linked to cervical carcinoma.